SEC Form 4 · accession 0000874015-15-000024
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah Boyce
Officer — Chief Business Officer
Period of report
Jan 15, 2015
Accepted (ET)
Jan 20, 2015 · 7:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 15, 2015 | A | 8,750 | A | — | — | Common Stock | 8,750 | 8,750 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.
- F2Grant 1/15/2015 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2016. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2019. The RSU is vested as to 0 shares on January 15, 2015.